onc Videos

Videos

Andrea Casadei-Gardini, MD, San Raffaele Research Hospital

Videos

Real-World Efficacy and Safety of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer

09/22/2023

A real-world analysis of durvalumab plus gemcitabine-cisplatin confirmed the results seen in previous clinical trials, supporting the use of this combination in clinical practice.

A real-world analysis of...

09/22/2023

Oncology

Videos

Exploring the Role of FGFR1 as a Therapeutic Target Among Patients With MCL

09/22/2023

Narendranath Epperla , MD, MS;

Narendranath Epperla, MD, MS, discusses the current research on fibroblast growth factor receptor-1 as an up-and-coming and viable therapeutic target for patients with mantle cell lymphoma.

Narendranath Epperla, MD, MS,...

09/22/2023

Oncology

Videos

Updates on the Safety, Efficacy of Mosunetuzumab Therapy for Patients With R/R Follicular Lymphoma

09/22/2023

Matthew Matasar , MD;

Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.

Matthew Matasar, MD, shares...

09/22/2023

Oncology

Videos

Novel Developments in the Multiple Myeloma Treatment Landscape

09/15/2023

Andrew Yee , MD;

Andrew Yee, MD, discusses new developments and possibilities in the treatment landscape for patients with multiple myeloma at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.

Andrew Yee, MD, discusses new...

09/15/2023

Oncology

Eugene Koay, MD, PhD, MD Anderson Cancer Center

Videos

Definitive Radiotherapy for Intrahepatic Cholangiocarcinoma With Extrahepatic Metastases

09/14/2023

Eugene Koay , MD, PhD;

Eugene Koay, MD, PhD, discusses a study which found liver radiotherapy for patients with intrahepatic cholangiocarcinoma and extrahepatic metastases was associated with a longer overall survival, compared with chemotherapy alone.

Eugene Koay, MD, PhD, discusses...

09/14/2023

Oncology

Videos

Antitumor Activity of Amivantamab Among Patients With METex14 Non-Small Cell Lung Cancer

09/13/2023

Alexander Spira , MD, PhD;

Alexander Spira, MD, PhD, discusses the efficacy of amivantamab among patients with METex14 NSCLC enrolled in the CHRYSALIS study, as presented at the 2023 World Conference on Lung Cancer.

Alexander Spira, MD, PhD,...

09/13/2023

Oncology

Videos

Promising Advances in the Treatment of Patients With Mantle Cell Lymphoma

09/13/2023

Michael Wang , MD;

At the 2023 Society of Hematologic Oncology Annual Meeting, Michael Wang, MD, reviews the latest research and treatment advances for patients with mantle cell lymphoma.

At the 2023 Society of...

09/13/2023

Oncology

Videos

Amivantamab, Lazertinib, and Chemotherapy Quadruplet Therapy Demonstrated Durable Response Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer

09/13/2023

Alexander Spira , MD, PhD;

Alexander Spira, MD, PhD, discusses updated results from the CHRYSALIS-2 study, in which amivantamab and lazertinib plus chemotherapy demonstrated durable and meaningful responses among patients with EGFR-mutated NSCLC, as presented at the...

Alexander Spira, MD, PhD,...

09/13/2023

Oncology

Videos

Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy Did Not Adversely Affect Surgical Outcomes Among Patients With Resectable Non-Small Cell Lung Cancer

09/12/2023

Tetsuya Mitsudomi , MD, PhD;

At the 2023 World Conference on Lung Cancer, Tetsuya Mitsudomi, MD, PhD, presented results which demonstrated the addition of perioperative durvalumab to neoadjuvant chemotherapy did not adversely affect surgical outcomes among patients with...

At the 2023 World Conference on...

09/12/2023

Oncology

Videos

Exploring Potential Novel Therapeutic Interventions for Patients With Early-Stage Myelodysplastic Syndromes

09/12/2023

Juan Jose Rodriguez-Sevilla , PhD;

Therapies targeting the biological mechanisms of pre-leukemic MDS may improve patient outcomes, according to data presented at the SOHO 2023 annual meeting by Juan Jose Rodriguez-Sevilla, PhD.

Therapies targeting the...

09/12/2023

Oncology

Recent News

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology